Sweden stimulates biotech start-ups:
This article was originally published in Clinica
The Karolinska Institute and the Swedish insurance company, SPP, have established a new venture capital fund to invest in R&D projects in the medical, biotechnology and medical technology fields. The Karolinska Investment Fund, of around SKr500 million ($61 million), is one of the first in Sweden to involve an academic institute linking up with an investment group. The fund will invest primarily in research projects at the Karolinska Institute and other medical institutions, universities and colleges in Sweden, thereby providing support for commercialisation of such projects. It is not restricted to investing in the institute or in Sweden, and although its main focus is on early-stage research, it may consider investing in more advanced projects and companies.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.